title: Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase.
abstract: Molecular modeling studies using the CHARMM method have been conducted to study the binding modes of aldose reductase inhibitors at the active site of aldose reductase. The energy minimized structures of aldose reductase with six structurally diverse inhibitors (spirofluorene-9,5'-imidazolidine-2',4'-dione (1), 9-fluoreneacetic acid (2), AL1576 (3), 2,7-difluoro-9-fluoreneacetic acid (4), FK366 (5), and Epalrestat (9)) indicate that the side chains of Tyr48, His110, and Trp111 can form numerous hydrogen bonds with either the carboxylate or the hydantoin group of the inhibitors while the side chains of Trp20, Trp111, and Phe122 are positioned to form aromatic-aromatic interactions. Of the three residues (Tyr 48, His 110, and Trp 111) that can form hydrogen bonds with the ionized portion of aldose reductase inhibitors, protonated His110 appears to play an important role in directing charged inhibitors to bind at the active site through charge interaction. Based on the binding mode of the inhibitors and their observed inhibitory activities, pharmacophore requirements for aldose reductase inhibitors are discussed.
authors.affiliation: National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA. yongslee@helix.nih.gov
authors.forename: Y S
authors.initials: YS
authors.lastname: Lee
authors.forename: Z
authors.initials: Z
authors.lastname: Chen
authors.forename: P F
authors.initials: PF
authors.lastname: Kador
mesh_terms: D000085:Acetates / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D001665:Binding Sites; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D005449:Fluorenes / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D005985:Glyceraldehyde / Q000378:metabolism; D006801:Humans; D007093:Imidazoles / Q000737:chemistry* / Q000378:metabolism*; D048289:Imidazolidines; D008958:Models, Molecular; D011799:Quinazolines / Q000737:chemistry / Q000378:metabolism; D012236:Rhodanine / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism; D013141:Spiro Compounds / Q000737:chemistry* / Q000378:metabolism*; D013329:Structure-Activity Relationship; D053778:Thiazolidines
chemical_list: D000085:Acetates; D004791:Enzyme Inhibitors; D005449:Fluorenes; D007093:Imidazoles; D048289:Imidazolidines; D011799:Quinazolines; D013141:Spiro Compounds; D053778:Thiazolidines; C116519:spirofluorene-9,5'-imidazolidine-2',4'-dione; C064920:FR 74366; D005985:Glyceraldehyde; C038131:epalrestat; C078694:9-fluoreneacetic acid; D012236:Rhodanine; D000449:Aldehyde Reductase